(Q44448395)

3 December 2017

title

Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction (English)

1 reference

3 December 2017

1 reference

8

Wolfgang C Winkelmayer

1 reference

3 December 2017

Waichi Wong

1

1 reference

3 December 2017

Nina Tolkoff-Rubin

2

1 reference

3 December 2017

Francis L Delmonico

3

1 reference

3 December 2017

Francesca Cardarelli

4

1 reference

3 December 2017

Susan L Saidman

5

1 reference

3 December 2017

Mary Lin Farrell

6

1 reference

3 December 2017

Vivian Shih

7

1 reference

3 December 2017

A Benedict Cosimi

9

1 reference

3 December 2017

Manuel Pascual

10

1 reference

3 December 2017

publication date

1 August 2004

1 reference

3 December 2017

published in

Clinical Transplantation

1 reference

3 December 2017

volume

18

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

341-348

1 reference

Chronic rejection and chronic cyclosporin toxicity in renal allografts

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Strategies to improve long-term outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

A role for uric acid in the progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Uric acid as a risk factor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Serum C-reactive protein in pediatric kidney and liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Immunosuppressive strategies in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

Prediction of cardiovascular risk using soluble cell adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00171.X

10.1111/J.1399-0012.2004.00171.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference